Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 7,764 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Withdrawn Phase 1 Interventional

REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts

NCT01496209
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Chronic Ischemic Cardiomyopathy
Interventions
Endomyocardial injections of allogeneic Human CSps, Endomyocardial injections of vehicle only.
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT03926130
View directory record Official record
Conditions
Crohn's Disease
Interventions
Mirikizumab, Ustekinumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
15 Years to 80 Years
Enrollment
1,158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
140
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Not applicable Interventional

Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for PTSD

NCT05242367
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Modius Spero active device, Sham device
Device
Lead sponsor
Neurovalens Ltd.
Industry
Eligibility
22 Years to 80 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Not applicable Interventional

Attention Training for Underserved Youth With Anxiety

NCT03028792
View directory record Official record
Conditions
Anxiety
Interventions
Attention Modification Program, Attention Control Condition
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
El Centro, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease

NCT03351738
View directory record Official record
Conditions
Stable Coronary Heart Disease
Interventions
MEDI5884, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
45 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
23
States / cities
Anniston, Alabama • Huntsville, Alabama • El Cajon, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 3 Interventional

Study of Efficacy of Ramelteon in Adults With Chronic Insomnia

NCT00671125
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 64 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Hot Springs, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 2 Interventional Results available

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

NCT00748215
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
Interventions
calcium aluminosilicate anti-diarrheal, placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 13, 2026, 5:50 PM EDT
Withdrawn Phase 3 Interventional

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT02392676
View directory record Official record
Conditions
Platinum Sensitive Relapsed Ovarian Cancer
Interventions
OLAPARIB, PLACEBO
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 96 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00622635
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 13, 2026, 5:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Transcranial Direct Current Stimulation and Modulation of Affect and Pain

NCT06989749
View directory record Official record
Conditions
We Are Not Studying a Disease or Condition
Interventions
Anodal tDCS, Cathodal tDCS, Sham tDCS
Other
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 13, 2026, 5:50 PM EDT
Not listed Phase 2 Interventional

Platelet Rich Plasma (PRP) Peri-urethral and Clitoral Injections for the Treatment of Female Orgasmic Disorder

NCT03189238
View directory record Official record
Conditions
Female Orgasmic Disorder
Interventions
Peri-urethral and clitoral injections
Biological
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 13, 2026, 5:50 PM EDT
Terminated Phase 4 Interventional Results available

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

NCT04547985
View directory record Official record
Conditions
Prolonged Grief Disorder
Interventions
Naltrexone HCl 50 MG Oral Tablet, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

NCT00481325
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
pexacerfont, escitalopram, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Mesa, Arizona • Burbank, California • Costa Mesa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 2 Interventional

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

NCT00279825
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Bingham Farms, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 13, 2026, 5:50 PM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

NCT02812147
View directory record Official record
Conditions
Parkinson Disease
Interventions
L-DOPS, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 13, 2026, 5:50 PM EDT
Terminated Phase 3 Interventional

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

NCT00577148
View directory record Official record
Conditions
Fatty Liver
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 13, 2026, 5:50 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis
Interventions
BMS-986278, BMS-986278 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 13, 2026, 5:50 PM EDT
Suspended Phase 2 Interventional

Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

NCT06240455
View directory record Official record
Conditions
Graves Disease
Interventions
WP1302, WP1302 placebo, methimazole
Drug · Combination Product
Lead sponsor
Worg Biotherapeutics Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Hunt, Arizona • Canoga Park, California • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 2 Interventional

An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder

NCT00057226
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Radafaxine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
21
States / cities
Cerritos, California • San Diego, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Placebo, Dacarbazine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Anaheim, California • La Verne, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 4 Interventional Results available

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

NCT05165485
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
76
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 13, 2026, 5:50 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

NCT02972658
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Lanabecestat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 13, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

NCT00465985
View directory record Official record
Conditions
Muckle Wells Syndrome
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
4 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 13, 2026, 5:50 PM EDT